EXAS vs MRKR · rev $2.76B vs rev $751.7K
EXACT Sciences Corporation (EXAS) versus Marker Therapeutics Inc (MRKR) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Marker Therapeutics Inc (MRKR) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported MRKR revenue for 2026-03-31 was $751.7K. Net income was -$3.2M. Revenue was down 69.2% from 2025-09-30 to 2026-03-31. MRKR currently screens at market cap $25.3M.
EXAS currently screens at market cap $20.03B. MRKR currently screens at market cap $25.3M.
Not investment advice. Open the EXAS and MRKR stock pages for the full models.
Not investment advice.